Emergent BioSolutions Inc. provided earnings guidance for the third quarter and full year 2022. For the quarter, the company expects total revenues of $230 - $270 million.

For the year, the company expects CDMO Revenues to be $105-$125 million and total revenues to be $1,150-$1,250 million.